Chest X-Ray AI solution Augmento X-Ray is a first of its kind commercially available US FDA cleared CADe Chest X-Ray AI solution. This CADe Chest X-Ray AI significantly reduces radiologist workload (30-50%) by seamlessly differentiating and analyzing chest radiographs. Its comprehensive coverage includes lung, pleura, cardiac issues, and foreign body detection. Unlike traditional point AI solutions identifying a specific pathology, Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It’s compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful. — By strategically deploying these AI tools, we aim to: • Reduce reporting turnaround time for radiology reports. • Improve medical diagnosis and treatment efficiency for lung diseases globally. • Increase patient screening throughput, especially in areas with limited resources. • Bridge the global shortage of radiologists and positively impact healthcare outcomes.

Radiology AI Deployment Platform Augmento is a US FDA Cleared Radiology AI deployment platform that seamlessly optimizes the radiology workflow. It comes with a unique combination of smart reporting and cutting-edge AI technology enabling productivity and quality gains. It connects various stakeholders in the radiology ecosystem with a click of a button and improves communication between them thus resulting in reduced reporting turnaround time of radiology reports. Quick and easy communication between physicians and technicians also helps radiologists to have a better understanding of a patient's condition and thus do better diagnosis and improve patient care. Augmento addresses the gap of a single-point AI deployment platform, which is not available in many existing solutions along with providing additional capabilities like Viewer, triaging capabilities, and automated report generation that enhances productivity, communication, and quality of reports for radiologists. Augmento is an open platform for healthcare providers to integrate AI models developed by DeepTek and other parties into their workflow. This means that healthcare providers can customize their use of AI to suit their specific needs and workflows. It helps radiologists and healthcare providers adopt AI tools with minimal disruption to their existing workflow. Currently, radiologists, imaging clinics, and hospitals are adding one AI at a time to the radiology workflow, which can be a time-consuming process. Augmento addresses this issue by creating an AI Deployment Platform, which is a thin client, seamless, and ubiquitous. Impact Augmento emerged as Singapore's National AI Platform, currently serving 500+ hospitals and imaging centers across India and APAC, touching about 1 million lives annually. The platform was adopted by the Singapore Health-tech Agency, now known as Synapxe, and deployed in five public hospitals, enabling the development and support of imaging AI models from various sources. Augmento's integration into Singapore's healthcare landscape revolutionized the imaging AI sector, providing a vendor-neutral platform that supports diverse AI models for different imaging modalities. Specific Results and Outcomes: • National Adoption: Augmento became the national AI platform for Singapore's healthcare, showcasing its pivotal role in the country's AI strategy. • Widespread Implementation: Augmento's deployment in key hospitals demonstrated its scalability and effectiveness in handling a large volume of medical data. • Vendor-Neutral Approach: Augmento's ability to support imaging AI models from different sources highlighted its versatility and commitment to inclusivity in the rapidly evolving field of medical imaging AI.

Genki Product description: AI powered Lung Screening solution Genki, our US FDA Cleared AI-powered lung health screening solution, complements Augmento. It efficiently analyzes chest scans for over 19 pathologies, operating both online and offline to reach even remote areas. Its compatibility with handheld X-ray machines further enhances accessibility. By automating the interpretation of chest X-rays, Genki offers immense potential for improving medical diagnosis and treatment efficiency for lung diseases such as tuberculosis, pneumonia, lung cancer, and chronic pulmonary diseases, all of which pose significant health challenges globally. This comprehensive and efficient solution can be used as an offline or online tool in hospitals, health centers, or mobile X-ray vans at hotspots, and also with handheld X-ray machines, making it accessible to remote areas with limited resources, where getting bulky X-ray machines is not feasible. With Genki, abnormals can be separated from normals within a minute, increasing patient screening throughput. Genki has also received Thai FDA approval and Kenya Board approval. The solution's effectiveness is backed by independent evaluations conducted by esteemed organizations like the Royal College of Radiology Thailand (RCRT), StopTB Partnership, Friends for International TB, and several others across the globe, which shows that the performance of AI is at par with human experts. Impact: Genki, in collaboration with the Greater Chennai Corporation (GCC), implemented a cutting-edge TB screening program. Leveraging artificial intelligence, Genki screened over 500,000 individuals, showcasing an impressive specificity and sensitivity rate of 97%, surpassing human experts. This resulted in a substantial increase in the yield of identified TB patients, elevating the detection rate from 20 to 500 per 100,000 screened. Genki's intervention significantly improved the early identification of TB patients, facilitating timely care and aligning with the broader goal of achieving a TB-free future in India. The initiative extended its impact across various states in India and 30+ districts in APAC, including Mongolia, Philippines, Singapore, Tunisia, and Thailand. Specific Results and Outcomes: • Increased Detection Rates: Genki's implementation led to a remarkable increase in TB patient detection rates, contributing to the success of the TB Free initiative. • Geographical Expansion: Genki's success in India paved the way for its adoption across diverse regions in APAC, further solidifying its position as a transformative force in the fight against tuberculosis. • COVID-19 Response: In the Philippines, Genki's adaptability was showcased during the peak of the COVID-19 pandemic, where it played a pivotal role in analyzing people, diagnosing pneumonia, including COVID-19 cases, and identifying other chest pathologies. This not only optimized healthcare resources but also showcased the platform's versatility.